The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

  • See Evidence submitted by expert panel for details.

Variant: NM_000277.2(PAH):c.734T>C (p.Val245Ala)

CA114372

632 (ClinVar)

Gene: PAH
Condition: phenylketonuria
Inheritance Mode: Autosomal recessive inheritance
UUID: 0129bef0-6e1d-4f6b-8e4e-2c05721902af

HGVS expressions

NM_000277.2:c.734T>C
NM_000277.2(PAH):c.734T>C (p.Val245Ala)
NC_000012.12:g.102852923A>G
CM000674.2:g.102852923A>G
NC_000012.11:g.103246701A>G
CM000674.1:g.103246701A>G
NC_000012.10:g.101770831A>G
NG_008690.1:g.69680T>C
NG_008690.2:g.110488T>C
NM_000277.1:c.734T>C
NM_001354304.1:c.734T>C
NM_000277.3:c.734T>C
ENST00000307000.7:c.719T>C
ENST00000549247.6:n.493T>C
ENST00000553106.5:c.734T>C

Pathogenic

Met criteria codes 3
PM5 PP4_Moderate PM3_Very Strong
Not Met criteria codes 3
PM2 PS3 PP3

Evidence Links 5

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
Phenylketonuria VCEP
PAH-specific ACMG/AMP criteria applied: PM5: V245L Pathogenic; PP4_Moderate: Seen in at least 7 MHP patients. Exclusion of a defect in tetrahydrobiopterin metabolism. Upgraded per ClinGen Metabolic Workgroup. (PMID:7981714; PMID:9298832; PMID:9634518); PM3_VeryStrong: V245A detected with IVS-12nt1, R252W, L194P (both P/LP), R408W (Path). Upgraded per ClinGen SVI Workgroup (PMID:7981714; PMID:9298832; PMID:8088845). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM5, PP4_Moderate, PM3_VeryStrong).
Met criteria codes
PM5
V245L Pathogenic
PP4_Moderate
Seen in at least 7 MHP patients. Exclusion of a defect in tetrahydrobiopterin metabolism. Upgraded per ClinGen Metabolic Workgroup.

PM3_Very Strong
V245A detected with IVS-12nt1, R252W, L194P (both P/LP), R408W (Path). Upgraded per ClinGen SVI Workgroup

Not Met criteria codes
PM2
ExAC MAF: 0.00114
PS3
V245A has PAH enzyme activities 63;39 (% of wt). 50% stated in PAHdb/BioPKU

PP3
Conflicting predictions of pathogenicity: Tolerated in SIFT, Damaging in Polyphen2, MutationTaster.
Approved on: 2018-09-28
Published on: 2019-04-05
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.